Blueprint Medicines Corporation BPMC
At closeJul 18, 2025, 4:00 PM EDT
52-week range unavailable
- YTD
- +48.43%
- 1 year
- +13.20%
- Market cap
- 8.37B
- Revenue (ttm)
- 562.12M
- Profit margin
- -27.70%
- Shares out
- 64.58M
- Forward P/E
- -137.72
- YTD return
- +48.43%
- 1-year return
- +13.20%
- Volume
- 2.98M
- Open
- 129.46
- Previous close
- 129.46
- Day's range
- 129.46 – 129.46
- Beta
- 0.83
- Analysts
- Hold
- Price target
- 130.29 (+0.6%)
2Y +31.91 (+32.71%)
Key statistics
- Enterprise value
- 8.42B
- PEG ratio
- 0.00
- Price / sales
- 14.89
- Price / book
- 24.43
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 55.50%
- Free cash flow
- -20.78M
- Total cash
- 576.24M
- Total debt
- 713.33M
- Return on equity
- -47.71%
- Short % of float
- 5.45%
- 50-day average
- 120.02
- 200-day average
- 100.22
Analyst view
Consensus: hold
- Target (low)
- 129.00
- Target (mean)
- 130.29
- Target (high)
- 135.00
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 17, 2025 | Wells Fargo | down | Overweight | Equal-Weight |
| Jun 5, 2025 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Jun 5, 2025 | UBS | main | Neutral | Neutral |
| Jun 4, 2025 | Citigroup | up | Sell | Neutral |
| Jun 3, 2025 | JMP Securities | down | Market Outperform | Market Perform |
| Jun 3, 2025 | Wolfe Research | down | Outperform | Peer Perform |
About Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- blueprintmedicines.com
News
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday 
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta 
This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday 
This Salesforce Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday 
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday 
Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday 
This Union Pacific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday 
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket 
Earnings Scheduled For May 1, 2025 
Earnings Scheduled For February 13, 2025
Your note
Sign in to keep a note on BPMC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARTER PERCY H | Officer | Stock Award(Grant) | Jul 16, 2025 | 0 |
| DURSO-BUMPUS DEBRA | Officer | Stock Award(Grant) | Jul 16, 2025 | 0 |
| HAVILAND KATE | Chief Executive Officer | Stock Award(Grant) | Jul 16, 2025 | 0 |
| HEWES LEMUEL BECKER | Officer | Stock Award(Grant) | Jul 16, 2025 | 0 |
| HURLEY ARIEL | Officer | Stock Award(Grant) | Jul 16, 2025 | 0 |
| LANDSITTEL MICHAEL | Chief Financial Officer | Stock Award(Grant) | Jul 16, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.39% | 6,710,708 | 868.77M | Mar 30, 2025 |
| Vanguard Group Inc | 10.28% | 6,640,523 | 859.68M | Mar 30, 2025 |
| Price (T.Rowe) Associates Inc | 8.39% | 5,415,837 | 701.13M | Mar 30, 2025 |
| Avoro Capital Advisors LLC | 5.96% | 3,850,000 | 498.42M | Mar 30, 2025 |
| Wellington Management Group, LLP | 4.76% | 3,073,306 | 397.87M | Mar 30, 2025 |
| State Street Corporation | 4.16% | 2,684,117 | 347.49M | Mar 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.11% | 2,009,220 | 260.11M | Mar 30, 2025 |
| T. Rowe Price New Horizons Fund, Inc. | 3.09% | 1,997,279 | 258.57M | Mar 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.47% | 1,595,096 | 206.50M | Mar 30, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 2.47% | 1,592,774 | 206.20M | May 30, 2025 |
| T. Rowe Price Health Sciences Fund, Inc. | 2.38% | 1,539,139 | 199.26M | Mar 30, 2025 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.11% | 1,362,970 | 176.45M | Apr 29, 2025 |